肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

O药 vs. K药论剑华山，11种癌症临床研究数据对比

2018-08-21 医药魔方 医药魔方

癌症临床研究
关注

默沙东KEYTRUDA（K药）和百时美施贵宝OPDIVO（O药）终于都成功在中国上市了，这让不少肿瘤患者看到了希望。 O药 、K药基本信息 俗称 O药 K药

默沙东KEYTRUDA（K药）和百时美施贵宝OPDIVO（O药）终于都成功在中国上市了，这让不少肿瘤患者看到了希望。 O药 、K药基本信息 俗称 O药 K药 商品名(英文) Opdivo Keytruda 商品名(中文) 欧狄沃 可瑞达 通用名(英文) Nivolumab Pembrolizumab 通用名(中文) 纳武单抗 派姆单抗 帕博利珠单抗 这么多名称，连从事医药工作的小编都看的懵逼，特别强调一下，帕博利珠单抗就是派姆单抗，并不是新出的另外一种，看到以上名称时请根据表格内自行对号入座。 O药 、K药的适应症 O药和K药目前所批的适应症均包括9-10种癌症： 编号 O药 K药 1 黑色素瘤 黑色素瘤 2 非小细胞肺癌 非小细胞肺癌 3 霍奇金淋巴瘤 霍奇金淋巴瘤 4 膀胱癌 膀胱癌 5 头颈部鳞状细胞癌 头颈部鳞状细胞癌 6 结直肠癌 高度卫星不稳定性实体瘤 结直肠癌 小肠肿瘤 肉瘤 子宫内膜癌 乳腺癌 甲状腺癌 胆管癌 膀胱癌 腹膜后腺癌 胃癌 食管癌 小细胞肺癌 胰腺癌 前列腺癌 肾细胞癌 7 肝癌 大B细胞淋巴瘤 8 肾癌 胃癌 9 尿路上皮癌 子宫颈癌 10 尿路上皮癌

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2019-02-20 doctor-chen9582

    #研究数据#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-24 lofter

    学习了感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-23 1e1c07bdm01(暂无匿称)

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-22 zhaojie88

    #O药#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-22 12498e0fm84暂无昵称

    #K药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 易水河

    学习学习很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 明月清辉

    谢谢分享，学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 kafei

    了解一下谢谢

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1989235, encodeId=a19e1989235ab, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Feb 20 13:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340455, encodeId=becd34045510, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C20CB8E4EBB36F5B821651C710BCB491/100, createdBy=18de1715848, createdName=lofter, createdTime=Fri Aug 24 06:45:17 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340247, encodeId=0cc034024eb0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Aug 23 05:05:01 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581356, encodeId=5a1c158135698, content=<a href='/topic/show?id=042a135e91d' target=_blank style='color:#2F92EE;'>#O药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13579, encryptionId=042a135e91d, topicName=O药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618722, encodeId=84271618e228c, content=<a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10615, encryptionId=89a810615bb, topicName=K药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae0619946966, createdName=12498e0fm84暂无昵称, createdTime=Wed Aug 22 15:21:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339881, encodeId=97a533988159, content=学习学习很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Aug 21 09:13:25 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339879, encodeId=a0583398e987, content=谢谢分享，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:08:39 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339862, encodeId=ace03398629f, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Aug 21 07:37:08 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339839, encodeId=c4c733983922, content=嗯嗯，学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 21 00:51:36 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 liumin1987

    嗯嗯，学习了。

    0

相关资讯

Nat Med：逆转缺失免疫T细胞可对抗致命脑瘤

T细胞功能障碍有助于癌症患者的肿瘤免疫逃逸，并且在胶质母细胞瘤（GBM）中尤其严重。近日，杜克癌症研究所的研究人员发现了GBM患者中缺失的T细胞的踪迹，它们被大量的隔离在骨髓中。骨髓中T细胞的隔离是T细胞功能障碍的肿瘤适应性模式，其逆转或可成为一种有前途的免疫治疗辅助手段。

Circulation：心衰竟可刺激肿瘤生长！

心脏衰竭（心衰，HF）的存活率已经有所提高，现如今，许多心衰患者死于包括癌症在内的非心源性因素。Wouter C. Meijers等人猜想心衰和癌症之间是否存在因果关系，并对此进行研究。研究人员采用易患肠道癌前病变的APCmin小鼠，通过堵塞血管造成大面积心肌梗死诱导心衰，然后监测肿瘤的生长。此外，为排除血流动力学障碍，研究人员采用异位心脏移植模型，即将梗死或假手术处理的心脏移植到受体小鼠，而且保

香港城市大学研发治疗癌症新技术 成本降99%

据香港《大公报》报道，近日，香港城市大学生物医学系研究团队研发出有助治疗各种癌症的新技术，用人体内的红血球制造出大量的胞外囊泡，作为运输治疗癌症药物的载体，成效达八成，成本及治疗费用仅是旧技术的1%。研究团队已在老鼠身上证明该技术不产生任何副作用。

Circulation：D-二聚体水平可预测冠心病患者的长期死亡率、心血管事件和癌症发病率

D-二聚体是交联纤维蛋白的降解产物，是高凝和血栓形成的标志物。D-二聚体中度升高与血管疾病患者的动静脉事件的风险相关。现研究人员对D-二聚体水平用于预测长期血管预后、特殊原因的死亡率以及新发癌症的作用进行评估。LIPID试验，将心肌梗死或不稳定心绞痛发生后5-38个月的患者随机分至普伐他汀（40mg/d）或安慰剂组。于起始和1年时检测D-二聚体水平。中位随访6.0年，总起来16年。7863位患者按

Circulation：心血管疾病患者的癌症风险较高？未必！

在社区观察性研究中，有证据显示，心血管疾病与较高的癌症发病率有关。2013年，Hasin等人的研究表明，心力衰竭和后续确诊癌症存在联系。这些发现在对心肌梗死人群的前瞻性队列研究中得到重现，丹麦的大规模心力衰竭队列研究中也观察到类似结果。然而，值得注意的是，这些流行病学研究并未区分射血分数保留型心力衰竭与射血分数降低型心力衰竭对这种相关性的影响差异。

Circulation：下肢动脉血栓患者需警惕是否已身患癌症！

静脉血栓是癌症的一种常见临床表现，但下肢动脉血栓与癌症是否存在相关性尚不明确。现研究人员对下肢动脉血栓患者的癌症风险及预后进行评估。研究人员根据丹麦国家医疗登记处获得首次确诊下肢动脉血栓的患者（1994-2013），随访至确诊罹患癌症、移民、死亡或截止2013年11月30日。计算标准化发病率，并构建一相匹配的无下肢动脉血栓的癌症患者作为比较队列，检验下肢动脉血栓形成对罹患癌症后的全因死亡率的影响。